Currently, biomarkers such as programmed death-ligand 1 (PD-L1) expression, microsatellite instability (MSI), and tumor mutational burden (TMB) are used to guide immunotherapy, but their predictive accuracy is limited. The gene discussed is CD274; the disease is neoplasm.